Zomedica (NYSEAMERICAN:ZOM – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, Yahoo Finance reports. Zomedica had a negative net margin of 104.92% and a negative return on equity of 6.51%. The company had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.20 million.
Zomedica Stock Down 3.1 %
Shares of ZOM stock opened at $0.23 on Friday. Zomedica has a 52-week low of $0.15 and a 52-week high of $0.41.
Institutional Trading of Zomedica
A number of hedge funds have recently made changes to their positions in the business. Money Concepts Capital Corp acquired a new position in Zomedica in the 4th quarter valued at about $25,000. West Michigan Advisors LLC acquired a new position in shares of Zomedica in the first quarter valued at approximately $28,000. ExodusPoint Capital Management LP bought a new position in shares of Zomedica during the second quarter worth approximately $38,000. Jane Street Group LLC lifted its holdings in shares of Zomedica by 62.9% during the fourth quarter. Jane Street Group LLC now owns 269,728 shares of the company’s stock worth $44,000 after buying an additional 104,143 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Zomedica by 68.6% in the third quarter. UBS Group AG now owns 210,693 shares of the company’s stock valued at $44,000 after acquiring an additional 85,736 shares during the period. 9.42% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Zomedica Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.
- Get a free copy of the StockNews.com research report on Zomedica (ZOM)
- Dollar General Offers Great Prices, but the Stock isn’t a Value
- Jabil Inc.: Blue Chip Tech Stock Pulls Back To Buy Zone
- Should You Bring The Luck Of The Irish To Your Investmets?
- The Big Banks Join Forces to Save First Republic Bank
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.